Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 8278287 siRNA compounds for inhibiting NRF2

Patent 8278287 was granted and assigned to Quark Pharmaceuticals Inc on October, 2012 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Currently, there are no issues on this topic.

Find more entities like US Patent 8278287 siRNA compounds for inhibiting NRF2

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo